JAMA Oncology
@jamaoncology.com
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
🌐 JAMAOncology.com
🌐 JAMAOncology.com
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern #LungAdenocarcinoma, but not for those with lepidic pattern alone. ja.ma/49BVIrh
January 15, 2026 at 4:30 PM
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern #LungAdenocarcinoma, but not for those with lepidic pattern alone. ja.ma/49BVIrh
The 2025 federal #Medicaid restrictions are projected to cause over 1 million missed #CancerScreening exams and over 150 excess #cancer deaths within 2 years, with substantial impact on younger and vulnerable adults. ja.ma/49waPmf
January 10, 2026 at 3:00 PM
The 2025 federal #Medicaid restrictions are projected to cause over 1 million missed #CancerScreening exams and over 150 excess #cancer deaths within 2 years, with substantial impact on younger and vulnerable adults. ja.ma/49waPmf
Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/4jzyDtZ
January 9, 2026 at 3:00 PM
Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/4jzyDtZ
CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after #cancer therapy in patients with solid tumors, especially among those with higher #chemotherapy exposure. ja.ma/3N9Any2
January 8, 2026 at 4:30 PM
CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after #cancer therapy in patients with solid tumors, especially among those with higher #chemotherapy exposure. ja.ma/3N9Any2
Gastric cancer is the fifth most diagnosed #cancer and the fifth leading cause of cancer-related deaths worldwide.
This @jama.com Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer.
ja.ma/4aO8sxp
This @jama.com Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer.
ja.ma/4aO8sxp
January 7, 2026 at 4:45 PM
Gastric cancer is the fifth most diagnosed #cancer and the fifth leading cause of cancer-related deaths worldwide.
This @jama.com Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer.
ja.ma/4aO8sxp
This @jama.com Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer.
ja.ma/4aO8sxp
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival.
ja.ma/3YnPJkQ
ja.ma/3YnPJkQ
January 6, 2026 at 2:00 PM
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival.
ja.ma/3YnPJkQ
ja.ma/3YnPJkQ
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group.
ja.ma/4ppJBUq
ja.ma/4ppJBUq
January 5, 2026 at 2:00 PM
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group.
ja.ma/4ppJBUq
ja.ma/4ppJBUq
Ocular toxic effects including keratopathy, blurred vision, cataract progression, and uveitis were common but generally reversible during mirvetuximab soravtansine therapy for FRα-positive gynecologic cancers. ja.ma/49mr6tQ
January 4, 2026 at 3:00 PM
Ocular toxic effects including keratopathy, blurred vision, cataract progression, and uveitis were common but generally reversible during mirvetuximab soravtansine therapy for FRα-positive gynecologic cancers. ja.ma/49mr6tQ
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
ja.ma/3MWrtE9
ja.ma/3MWrtE9
January 4, 2026 at 1:00 PM
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
ja.ma/3MWrtE9
ja.ma/3MWrtE9
A 52-year-old woman had presented with persistent inflammatory edema of the lower limb and a history of squamous cell #carcinoma.
What is your diagnosis? ja.ma/4bmRVAC
What is your diagnosis? ja.ma/4bmRVAC
January 3, 2026 at 1:00 PM
A 52-year-old woman had presented with persistent inflammatory edema of the lower limb and a history of squamous cell #carcinoma.
What is your diagnosis? ja.ma/4bmRVAC
What is your diagnosis? ja.ma/4bmRVAC
Editorial: MELATORCH trial supports PD-1 blockade as standard care over chemotherapy for advanced acral melanoma, yet limited long-term benefit signals the need for novel therapeutic strategies. ja.ma/4jejiyP
January 2, 2026 at 5:00 PM
Editorial: MELATORCH trial supports PD-1 blockade as standard care over chemotherapy for advanced acral melanoma, yet limited long-term benefit signals the need for novel therapeutic strategies. ja.ma/4jejiyP
In a phase 3 trial, toripalimab improved progression-free survival over dacarbazine as first-line treatment in advanced #melanoma predominantly of acral subtype, with an acceptable safety profile. ja.ma/4pkD2Ci
January 2, 2026 at 4:30 PM
In a phase 3 trial, toripalimab improved progression-free survival over dacarbazine as first-line treatment in advanced #melanoma predominantly of acral subtype, with an acceptable safety profile. ja.ma/4pkD2Ci
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
ja.ma/4pir6Rs
ja.ma/4pir6Rs
January 1, 2026 at 2:00 PM
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
ja.ma/4pir6Rs
ja.ma/4pir6Rs
Dexrazoxane use in pediatric AML rose from 0.5% to 98.5% between 2010 and 2021, coinciding with a 50% reduction in ICU-level cardiovascular care, supporting rapid adoption of dexrazoxane for cardioprotection with intensive chemotherapy. ja.ma/4bdtHc4
January 1, 2026 at 12:00 PM
Dexrazoxane use in pediatric AML rose from 0.5% to 98.5% between 2010 and 2021, coinciding with a 50% reduction in ICU-level cardiovascular care, supporting rapid adoption of dexrazoxane for cardioprotection with intensive chemotherapy. ja.ma/4bdtHc4
Cribriform morphology predicted 15-year metastasis in #ProstateCancer, with radiotherapy plus neoadjuvant ADT reducing this risk, while cribriform-negative patients did not benefit from early radical treatment for metastasis prevention. ja.ma/4pm5W5h
December 31, 2025 at 12:00 PM
Cribriform morphology predicted 15-year metastasis in #ProstateCancer, with radiotherapy plus neoadjuvant ADT reducing this risk, while cribriform-negative patients did not benefit from early radical treatment for metastasis prevention. ja.ma/4pm5W5h
From @jama.com: Among #Medicare Advantage beneficiaries aged 75 years or older with #cancer, a lay health worker–administered telephone assessment reduced acute care use, including 68% lower odds of hospitalization, compared with standard care.
ja.ma/4jn7ZVk
ja.ma/4jn7ZVk
December 30, 2025 at 5:30 PM
From @jama.com: Among #Medicare Advantage beneficiaries aged 75 years or older with #cancer, a lay health worker–administered telephone assessment reduced acute care use, including 68% lower odds of hospitalization, compared with standard care.
ja.ma/4jn7ZVk
ja.ma/4jn7ZVk
Both combined and progestin-only contraceptives are linked to increased #BreastCancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. ja.ma/3Yjq8cO
December 30, 2025 at 12:00 PM
Both combined and progestin-only contraceptives are linked to increased #BreastCancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. ja.ma/3Yjq8cO
From @jama.com: After new out-of-pocket caps in 2024, initial and 60-day fill rates increased for #Medicare beneficiaries without low-income subsidies, though affordability barriers remain for specialty oral #anticancer drugs.
ja.ma/4seI0mQ
ja.ma/4seI0mQ
December 29, 2025 at 5:30 PM
From @jama.com: After new out-of-pocket caps in 2024, initial and 60-day fill rates increased for #Medicare beneficiaries without low-income subsidies, though affordability barriers remain for specialty oral #anticancer drugs.
ja.ma/4seI0mQ
ja.ma/4seI0mQ
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. ja.ma/4pZZsdk
December 29, 2025 at 3:00 PM
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. ja.ma/4pZZsdk
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. ja.ma/49bnKtv
December 29, 2025 at 1:00 PM
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. ja.ma/49bnKtv
💬 Editorial: Consistent long-term physical activity was linked to optimally reduced risk of digestive system cancers. ja.ma/4avYH6U
December 29, 2025 at 1:00 PM
💬 Editorial: Consistent long-term physical activity was linked to optimally reduced risk of digestive system cancers. ja.ma/4avYH6U
Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity. ja.ma/4pxFHsJ
December 28, 2025 at 12:00 PM
Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity. ja.ma/4pxFHsJ
Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. ja.ma/3YQ7tFy
December 27, 2025 at 3:00 PM
Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. ja.ma/3YQ7tFy
A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis. ja.ma/4sdrymH
December 27, 2025 at 1:00 PM
A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis. ja.ma/4sdrymH
The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for #LungCancer screening, but gains in scan completion were limited. ja.ma/48QffoY
December 26, 2025 at 5:00 PM
The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for #LungCancer screening, but gains in scan completion were limited. ja.ma/48QffoY